Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zenas BioPharma (ZBIO) Long-Term Investments (2025)

Zenas BioPharma has reported Long-Term Investments over the past 1 years, most recently at $17.3 million for Q4 2025.

  • Quarterly results put Long-Term Investments at $17.3 million for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $17.3 million (changed N/A YoY), and the annual figure for FY2025 was $17.3 million, changed.
  • Long-Term Investments for Q4 2025 was $17.3 million at Zenas BioPharma, up from $10.7 million in the prior quarter.
  • Over the last five years, Long-Term Investments for ZBIO hit a ceiling of $17.3 million in Q4 2025 and a floor of $1.6 million in Q2 2025.